Biocon Biologics to Acquire Viatris Biosimilars Assets for up to USD 3.335 billion in Stock and Cash
Biocon Biologics Ltd., a subsidiary of Biocon Ltd announced today that it has entered into a definitive agreement with its partner Viatris Inc. . Accordingly, Biocon Biologics Ltd will acquire Viatris’ biosimilars business to create a unique fully integrated global biosimilars enterprise. Viatris will receive consideration of up to USD 3.335 billion, including cash up to USD 2.335 billion and Compulsorily Convertible Preference Shares in BBL, valued at USD 1 billion.